Bayer AG
XETRA:BAYN
P/FCFE
Price to FCFE
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | P/FCFE | ||||
---|---|---|---|---|---|
DE |
Bayer AG
XETRA:BAYN
|
26.5B EUR | 9.5 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -40 845 137.7 | |
US |
Eli Lilly and Co
NYSE:LLY
|
695.1B USD | 134.3 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
3.9T DKK | 57.5 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 2 143.3 | ||
JP |
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
|
82T JPY | -3 381.2 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
357.5B USD | 28.7 | ||
US |
Merck & Co Inc
NYSE:MRK
|
321.5B USD | 24.5 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
176B GBP | 49.8 | ||
CH |
Novartis AG
SIX:NOVN
|
182.2B CHF | 22 | ||
CH |
Roche Holding AG
SIX:ROG
|
177.1B CHF | 17.7 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.